Personalized Vaccine For 'Deadliest Major Cancer' Keeps Patients Alive 6 Years Later

Key Points:

• Researchers presented promising results on a personalized mRNA vaccine for pancreatic cancer at the American Association for Cancer Research (AACR) annual meeting, showing that seven patients who responded to the vaccine remain alive up to six years after treatment.
• The vaccine is custom-made for each patient using genetic material from their tumors, aiming to train the immune system to recognize and prevent cancer recurrence, a significant breakthrough given pancreatic cancer's typically poor prognosis.
• The phase 1 trial involved 16 patients with operable pancreatic cancer who received the vaccine after surgery, combined with immunotherapy and chemotherapy; responders showed a much higher survival rate compared to non-responders.
• Despite the encouraging findings, pancreatic cancer remains difficult to treat due to late diagnoses and limited immune targets, and it is unclear if the vaccine will be effective in advanced stages of the disease.
• A global phase 2 clinical trial is currently underway to further evaluate the vaccine’s efficacy, with hopes that this approach could eventually benefit more patients and potentially other cancer types.